ERBB2 and breast carcinoma: Assuming they are using the same traits as those in the Choosing Wisely campaign for patients > 70 years with HR-positive, HER2-negative breast cancers, this only describes phenotypic traits, leaving room for guideline supplementation regarding patients’ genomic data.